This past week, David H. Crean, PhD, Managing Director and head of our Life Sciences and Healthcare Practice Group, spent time reviewing the >400 life science opportunities that were presented to him and our investment banking firm in 2017 in which entrepreneurs and business owners were looking for either capital financing, sell-side M&A, strategic advisory services or partnering/ licensing. Nearly invariably, each investment pitch lacked the complete and necessary material to tell the comprehensive story that would be compelling for an investor to write a check. These entrepreneurs are very smart and passionate about their mission but need to recognize and think like investors or strategic buyers. Investors see and hear many investment opportunities and you need to be differentiated and stand out from the masses.(more…)
A wise advisor once said, “Obvious buyers are obvious”. This truism serves as a recommendation to sellers to seek beyond the obvious buyers when constructing a list of potential acquirers
Obvious buyers typically identified include a mix of direct competitors and the large players that dominate the sector. Many investment banks often provide sellers with a list of the 25 or so obvious buyers, resulting in the seller feeling a false sense of comfort because all the names of the potential acquirers that they are familiar with are on the list. And, while many of these companies may represent high-fit potential acquirers, the seller is missing out on engaging with a large number of less obvious, high-fit potential acquirers. These acquirers have a strong strategic rationale to acquire and a resulting high willingness to pay a premium purchase price.
When owners decide to sell their company, one of the first things they consider is building a list of high-fit potential acquirers for the business. With private equity (financial) acquirers becoming so abundant in the last 10 years (over 2,500 in North America), the list of potential acquirers to approach in the sale process is likely to consist of both strategic and financial acquirers.
You received an inquiry or offer to buy your company - now what?
An unsolicited acquisition offer for your business can come as a surprise. If you haven’t considered selling your company or you are 3-5 years out from your planned exit, you may be caught off guard. This can lead to stress and worry about making the right decision in order maximize the sales price.
No matter what your industry of focus is, there are some key strategies you should employ when faced with an inquiry or offer to acquire your company. The decision you make must be an informed decision in alignment with your objectives.(more…)
Objective Capital’s David H. Crean to Serve as Guest Panelist at LaunchBio Event, November 14, 2017
San Diego, November 9, 2017 — Objective Capital Partners, a middle market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, has been invited to speak as a guest panelist at LaunchBio Series Event for life science companies entitled BIO Buck$ Fast Forward: A Start-ups Guide to Investment Banks. Dr. Crean will be joined by Charlie Adams, Cantor Fitzgerald and Tony Grover, VP of Business Development at Banyan Biomarker.(more…)
Objective Capital’s David H. Crean to be Guest Panelist at ACG Orange County's CEO Signature Event on November 15, 2017
San Diego, November 6, 2017 — Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, will be a guest panelist speaker at ACG Orange County’s CEO Signature Event entitled SoCal Capital Summit on November 15, 2017. Dr. Crean and the fellow panelists will address M&A Healthcare Trends and Opportunities. He will be joined by Greg Cunniff, CFO, NVISION Eye Centers, and Steven Shill, Partner and National Healthcare Practice Leader at BDO.(more…)
San Diego, CA- October 4, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A, healthcare & life sciences and valuation advisory services, is pleased to announce that Channing, Hamlet, one of its Managing Directors, will serve as Keynote Speaker as part of the Million Dollar Curriculum on “What’s Your Business Really Worth?”. The program will be held on October 11, 2017 at Corporate Alliance Center, 9171 Towne Centre Drive, San Diego, CA 92122 from 8 AM- 12 PM. The event is sponsored and presented by Cade & Company.(more…)
Objective Capital Partners Acted as Financial Advisor to Practicing Excellence
San Diego, CA- September 25, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A, healthcare & life sciences and valuation advisory services, is pleased to announce the successful closing of one of its advisory engagements with Practicing Excellence upon its strategic alliance with and investment from NRC Health. Practicing Excellence, the developer of an online skill-building platform, connects clinicians to practical, evidence-based, colleague-tested tools designed to enhance the delivery of patient care and improve the overall physician experience.(more…)
Objective Capital Partners Acted as Exclusive Financial Advisor to Troxel
San Diego, CA- September 5, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A, healthcare & life sciences and valuation advisory services, is pleased to announce the successful closing of one of its advisory engagements with Troxel, the world’s leading provider of ASTM/SEI certified equestrian helmets, upon its acquisition by Weaver Leather, LLC. Objective Capital Partners acted as exclusive financial advisor to Troxel.(more…)
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.